Abstract
Purpose
Race/ethnicity have been previously shown to significantly affect survival after diagnosis with glioblastoma, but the cause of this survival difference is not known. The aim of this study was to examine variation in treatment pattern and time to treatment by race/ethnicity, and the extent to which this affects survival.
Methods
Data were obtained from the National Cancer Database (NCDB) for adults ≥ 40 with glioblastoma from 2004 to 2016 (N = 68,979). Treatment patterns and time to treatment by race/ethnicity were compared using univariable and multivariable logistic and linear regression models, respectively, and adjusted for known prognostic factors and factors potentially affecting health care access.
Results
Black non-Hispanics (BNH) and Hispanics were less likely to receive radiation and less likely to receive chemotherapy as compared to White non-Hispanics (WNH). Time to radiation initiation was ~ 2 days longer and time to chemotherapy initiation was ~ 4 days longer in both groups in comparison to WNH.
Conclusion
Both race/ethnicity and treatment timing significantly affected survival time, and this association remained after adjustment for known prognostic factors. Additional research is necessary to disentangle the specific causal factors, and the mechanism with which they affect survival.
Similar content being viewed by others
Data availability
The National Cancer Database (NCDB) data that support the findings of this study are available from American College of Surgeons and the American Cancer Society. Restrictions apply to the availability of these data, which were used under license for this study. Data are available at https://www.facs.org/quality-programs/cancer/ncdb for investigators at Commission on Cancer (CoC) accredited facilities with an approved data request.
References
Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2020) CBTRUS Statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol 22:iv1–iv96. https://doi.org/10.1093/neuonc/noaa200
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330
Dressler EV, Liu M, Garcia CR, Dolecek TA, Pittman T, Huang B, Villano JL (2019) Patterns and disparities of care in glioblastoma. Neurooncol Pract 6:37–46. https://doi.org/10.1093/nop/npy014
Lu VM, Shah AH, Eichberg DG, Quinones-Hinojosa A, Esquenazi Y, Komotar RJ, Ivan ME (2020) Geographic disparities in access to glioblastoma treatment based on Hispanic ethnicity in the United States: insights from a national database. J Neurooncol 147:711–720. https://doi.org/10.1007/s11060-020-03480-1
Patel NP, Lyon KA, Huang JH (2019) The effect of race on the prognosis of the glioblastoma patient: a brief review. Neurol Res 41:967–971. https://doi.org/10.1080/01616412.2019.1638018
Mandel JJ, Youssef M, Nam J, Patel AJ, Jalali A, Ludmir EB, Liu D, Wu J, Armstrong G, Huse J, Bondy M, de Groot JF (2019) Effect of health disparities on overall survival of patients with glioblastoma. J Neurooncol 142:365–374. https://doi.org/10.1007/s11060-019-03108-z
Seidlitz A, Siepmann T, Löck S, Juratli T, Baumann M, Krause M (2015) Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme. Radiat Oncol 10:172. https://doi.org/10.1186/s13014-015-0478-5
Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS (2018) Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol 4:1254–1262. https://doi.org/10.1001/jamaoncol.2018.1789
Hauser A, Dutta SW, Showalter TN, Sheehan JP, Grover S, Trifiletti DM (2018) Impact of academic facility type and volume on post-surgical outcomes following diagnosis of glioblastoma. J Clin Neurosci 47:103–110. https://doi.org/10.1016/j.jocn.2017.10.087
Rhome R, Fisher R, Hormigo A, Parikh RR (2016) Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma. J Neurooncol 128:241–250. https://doi.org/10.1007/s11060-016-2101-5
Bohn A, Braley A, Rodriguez de la Vega P, Zevallos JC, Barengo NC (2018) The association between race and survival in glioblastoma patients in the US: a retrospective cohort study. PLoS ONE 13:e0198581. https://doi.org/10.1371/journal.pone.0198581
Warren KT, Liu L, Liu Y, Milano MT, Walter KA (2019) The impact of timing of concurrent chemoradiation in patients with high-grade glioma in the era of the stupp protocol. Front Oncol 9:186–186. https://doi.org/10.3389/fonc.2019.00186
Ahn S, Park JS, Song JH, Jeun SS, Hong YK (2020) Effect of a time delay for concomitant chemoradiation after surgery for newly diagnosed glioblastoma: a single-institution study with subgroup analysis according to the extent of tumor resection. World Neurosurg 133:e640–e645. https://doi.org/10.1016/j.wneu.2019.09.122
Buszek SM, Al Feghali KA, Elhalawani H, Chevli N, Allen PK, Chung C (2020) Optimal timing of radiotherapy following gross total or subtotal resection of glioblastoma: a real-world assessment using the national cancer database. Sci Rep 10:4926. https://doi.org/10.1038/s41598-020-61701-z
Katsigiannis S, Krischek B, Barleanu S, Grau S, Galldiks N, Timmer M, Kabbasch C, Goldbrunner R, Stavrinou P (2019) Impact of time to initiation of radiotherapy on survival after resection of newly diagnosed glioblastoma. Radiat Oncol 14:73. https://doi.org/10.1186/s13014-019-1272-6
Pollom EL, Fujimoto DK, Han SS, Harris JP, Tharin SA, Soltys SG (2018) Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival. J Radiat Res 59:i11–i18. https://doi.org/10.1093/jrr/rrx103
Wright JM, Hodges TR, Wright CH, Gittleman H, Zhou X, Duncan K, Kruchko C, Sloan A, Barnholtz-Sloan JS (2019) Racial/ethnic differences in survival for patients with gliosarcoma: an analysis of the National cancer database. J Neurooncol 143:349–357. https://doi.org/10.1007/s11060-019-03170-7
National Cancer Database (2020) National Cancer Database Participant User File: 2017 Data Dictionary. https://www.facs.org/-/media/files/quality-programs/cancer/ncdb/puf_data_dictionary_2017.ashx. Accessed 15 Feb 2021
R Core Team (2020) R: A language and environment for statistical computing. R foundation for statistical computing. http://www.R-project.org/. Accessed 21 July 2020
Kassambara A, Kosinski M, Biecek P, Fabian S (2020) survminer: Drawing Survival Curves using 'ggplot2'. https://rpkgs.datanovia.com/survminer/index.html. Accessed 21 July 2020
Heinzen E, Sinnwell J, Atkinson E, Gunderson T, Dougherty G, Votruba P, Lennon R, Hanson A, Goergen K, Lundt E, Broderick B, McCullough M (2020) arsenal: an arsenal of ‘R’ functions for large-scale statistical summaries. https://github.com/mayoverse/arsenal. Accessed 22 July 2020
Wickham H, Averick M, Bryan J, Chang W, McGowan LDA, François R, Grolemund G, Hayes A, Henry L, Hester J, Kuhn M, Pedersen TL, Miller E, Bache SM, Müller K, Ooms J, Robinson D, Seidel DP, Spinu V, Takahashi K, Vaughan D, Wilke C, Woo K, Yutani H (2019) Welcome to the Tidyverse. J Open Source Softw 4:1686. https://doi.org/10.21105/joss.01686
Dardis C (2018) survMisc: miscellaneous functions for survival data. https://github.com/dardisco/survMisc. Accessed 22 July 2020
Soetaert K (2017) diagram: functions for visualising simple graphs (networks), plotting flow diagrams. https://CRAN.R-project.org/package=diagram. Accessed 24 July 2020
Therneau TM (2020) A package for survival analysis in R. R package version 3.2-7. https://CRAN.R-project.org/package=survival. Accessed 15 Feb 2021
Mogensen UB, Ishwaran H, Gerds TA (2012) Evaluating random forests for survival analysis using prediction error curves. J Stat Softw 50:23. https://doi.org/10.18637/jss.v050.i11
Chandra A, Rick JW, Dalle Ore C, Lau D, Nguyen AT, Carrera D, Bonte A, Molinaro AM, Theodosopoulos PV, McDermott MW, Berger MS, Aghi MK (2018) Disparities in health care determine prognosis in newly diagnosed glioblastoma. Neurosurg Focus 44:E16. https://doi.org/10.3171/2018.3.Focus1852
Cote DJ, Ostrom QT, Gittleman H, Duncan KR, CreveCoeur TS, Kruchko C, Smith TR, Stampfer MJ, Barnholtz-Sloan JS (2019) Glioma incidence and survival variations by county-level socioeconomic measures. Cancer 125:3390–3400. https://doi.org/10.1002/cncr.32328
Brown DA, Himes BT, Kerezoudis P, Chilinda-Salter YM, Grewal SS, Spear JA, Bydon M, Burns TC, Parney IF (2018) Insurance correlates with improved access to care and outcome among glioblastoma patients. Neuro Oncol 20:1374–1382. https://doi.org/10.1093/neuonc/noy102
Liu EK, Yu S, Sulman EP, Kurz SC (2020) Racial and socioeconomic disparities differentially affect overall and cause-specific survival in glioblastoma. J Neurooncol 149:55–64. https://doi.org/10.1007/s11060-020-03572-y
Wang T, Pham A, Yoo S, Attenello FJ, Jennelle R, Wagle N, Chang EL, Zada G (2020) Identifying disparities in care in treating glioblastoma: a retrospective cohort study of patients treated at a safety-net versus private hospital setting. World Neurosurg 137:e213–e220. https://doi.org/10.1016/j.wneu.2020.01.133
Cioffi G, Cote DJ, Ostrom QT, Kruchko C, Barnholtz-Sloan JS (2020) Association between urbanicity and surgical treatment among patients with primary glioblastoma in the United States. Neurooncol Pract 7:299–305. https://doi.org/10.1093/nop/npaa001
Lopez Ramos C, Brandel MG, Steinberg JA, Wali AR, Rennert RC, Santiago-Dieppa DR, Sarkar RR, Pannell JS, Murphy JD, Khalessi AA (2019) The impact of traveling distance and hospital volume on post-surgical outcomes for patients with glioblastoma. J Neurooncol 141:159–166. https://doi.org/10.1007/s11060-018-03022-w
Boffa DJ, Rosen JE, Mallin K, Loomis A, Gay G, Palis B, Thoburn K, Gress D, McKellar DP, Shulman LN, Facktor MA, Winchester DP (2017) Using the National Cancer database for outcomes research: a review. JAMA Oncol 3:1722–1728. https://doi.org/10.1001/jamaoncol.2016.6905
Lerro CC, Robbins AS, Phillips JL, Stewart AK (2013) Comparison of cases captured in the national cancer data base with those in population-based central cancer registries. Ann Surg Oncol 20:1759–1765. https://doi.org/10.1245/s10434-013-2901-1
Ostrom QT, Kinnersley B, Armstrong G, Rice T, Chen Y, Wiencke JK, McCoy LS, Hansen HM, Amos CI, Bernstein JL, Claus EB, Eckel-Passow JE, Il’yasova D, Johansen C, Lachance DH, Lai RK, Merrell RT, Olson SH, Sadetzki S, Schildkraut JM, Shete S, Rubin JB, Andersson U, Rajaraman P, Chanock SJ, Linet MS, Wang Z, Yeager M, Houlston RS, Jenkins RB, Wrensch MR, Melin B, Bondy ML, Barnholtz-Sloan JS (2018) Age-specific genome-wide association study in glioblastoma identifies increased proportion of ’lower grade glioma’-like features associated with younger age. Int J Cancer 143:2359–2366. https://doi.org/10.1002/ijc.31759
Funding
QTO is supported by a Research Training Grant from the Cancer Prevention and Research Institute of Texas (CPRIT; RP160097T).
Author information
Authors and Affiliations
Contributions
QTO and JSB designed the project. QTO, GC and NP planned analytic approach. QTO performed all analyses. QTO and HK wrote the manuscript. All authors discussed the results and commented on the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Ostrom, Q.T., Krebs, H.L., Patil, N. et al. Racial/ethnic disparities in treatment pattern and time to treatment for adults with glioblastoma in the US. J Neurooncol 152, 603–615 (2021). https://doi.org/10.1007/s11060-021-03736-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-021-03736-4